M3 Biotechnology Begins Testing of Alzheimer’s Therapy in Adults with the Disease

M3 Biotechnology Begins Testing of Alzheimer’s Therapy in Adults with the Disease

Source: 
CP Wire
snippet: 
  • NDX-1017 is intented to halt or reverse Alzheimer's
  • It a completely different mechanism of action than other drug candidates currently in development
  • NDX-1017 addresses receptors of proteins known as hepatocyte growth factors